Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Update

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 21,719 shares, a drop of 66.7% from the November 30th total of 65,284 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average trading volume of 101,515 shares, the short-interest ratio is currently 0.2 days. Based on an average trading volume of 101,515 shares, the short-interest ratio is currently 0.2 days. Approximately 0.4% of the shares of the company are short sold.

Neuphoria Therapeutics Trading Down 1.8%

Shares of Neuphoria Therapeutics stock traded down $0.07 during mid-day trading on Friday, reaching $3.72. 24,284 shares of the stock were exchanged, compared to its average volume of 562,392. Neuphoria Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $21.40. The company has a market cap of $20.00 million, a price-to-earnings ratio of -0.76 and a beta of 0.51. The firm has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $8.12.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($4.41) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, research analysts predict that Neuphoria Therapeutics will post -1.56 EPS for the current fiscal year.

Insider Transactions at Neuphoria Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp bought 639,110 shares of the business’s stock in a transaction that occurred on Tuesday, October 21st. The stock was purchased at an average cost of $5.14 per share, for a total transaction of $3,285,025.40. Following the purchase, the insider directly owned 875,328 shares in the company, valued at $4,499,185.92. This trade represents a 270.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Neuphoria Therapeutics

An institutional investor recently bought a new position in Neuphoria Therapeutics stock. Persistent Asset Partners Ltd bought a new stake in shares of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 4,908 shares of the company’s stock, valued at approximately $58,000. Persistent Asset Partners Ltd owned about 0.21% of Neuphoria Therapeutics as of its most recent filing with the SEC. 15.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on NEUP shares. Maxim Group boosted their price objective on shares of Neuphoria Therapeutics from $18.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, September 11th. Weiss Ratings downgraded Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, October 8th. Wall Street Zen cut Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. HC Wainwright decreased their price objective on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, December 5th. Finally, Zacks Research cut Neuphoria Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, December 8th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $21.00.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.